1
by Ho, Chuong, Lau, Andrea, Cimon, Karen, Farrah, Kelly
Published 2012
Canadian Agency for Drugs and Technologies in Health
...), and other gram-negative bacteria may produce the enzymes known as extended spectrum beta-lactamases (ESBL...

2
Published 2011
Canadian Agency for Drugs and Technologies in Health
... producer and broker of health technology assessments. Health care decision-makers rely on our work to make...

3
Published 2011
Canadian Agency for Drugs and Technologies in Health
... producer and broker of health technology assessments. Health care decision-makers rely on our work to make...

4
Published 2016
Canadian Agency for Drugs and Technologies in Health
... in these patients. This report is an update of two previous reports on this topic, produced by the Canadian Agency...

5
Published 2016
Canadian Agency for Drugs and Technologies in Health
... in these patients. This report is an update of two previous reports on this topic, produced by the Canadian Agency...

6
Published 2014
Canadian Agency for Drugs and Technologies in Health
...The purpose of this review is to provide an update of a Rapid Response report produced by CADTH...

7
Published 2014
Canadian Agency for Drugs and Technologies in Health
...The purpose of this review is to provide an update of a Rapid Response report produced by CADTH...

8
Published 2015
Canadian Agency for Drugs and Technologies in Health
... alone. The finding of this report can help produce clinical evidence as well as policy directions...

9
by Peprah, Kwakye, Severn, Melissa
Published 2019
CADTH
...In 2017, CADTH produced a Rapid Response report summarizing evidence on the comparative clinical...

10
by Peprah, Kwakye, Severn, Melissa
Published 2019
CADTH
...In 2017, CADTH produced a Rapid Response report summarizing evidence on the comparative clinical...

11
by Wood, Ronald, Bassett, Kenneth, Foerster, Vicki, Spry, Carolyn
Published 2011
Canadian Agency for Drugs and Technologies in Health
..., where increasing the magnet strength has produced more sophisticated device capabilities. A systematic...

12
by Wood, Ronald, Bassett, Kenneth, Foerster, Vicki, Spry, Carolyn
Published 2011
Canadian Agency for Drugs and Technologies in Health
..., where increasing the magnet strength has produced more sophisticated device capabilities. A systematic...

13
Published 2015
Canadian Agency for Drugs and Technologies in Health
... alone. The finding of this report can help produce clinical evidence as well as policy directions...

14
by Pohar, Ron, Farrah, Kelly
Published 2019
Canadian Agency for Drugs and Technologies in Health
... tissue, and the time required to produce a written pathology reports. The potentially low diagnostic...

15
by Pohar, Ron, Farrah, Kelly
Published 2019
Canadian Agency for Drugs and Technologies in Health
... tissue, and the time required to produce a written pathology reports. The potentially low diagnostic...

16
Published 2014
Canadian Agency for Drugs and Technologies in Health
... produce adverse events and they also have a slower onset of action, during which there may be an increase...

17
by Banerjee, Srabani, McCormack, Suzanne
Published 2020
Canadian Agency for Drugs and Technologies in Health
...., fentanyl), propofol, and ketamine. Ketamine is a N-methyl-D aspartate receptor antagonist that produces a...

18
Published 2014
Canadian Agency for Drugs and Technologies in Health
... produce adverse events and they also have a slower onset of action, during which there may be an increase...

19
Published 2015
Canadian Agency for Drugs and Technologies in Health
... plasma cells (of greater than or equal to 5%). Measurement of the protein manifestations produced...

20
Published 2015
Canadian Agency for Drugs and Technologies in Health
... plasma cells (of greater than or equal to 5%). Measurement of the protein manifestations produced...